Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

enovis - ENOV

ENOV

Close Chg Chg %
26.95 -2.30 -8.52%

Closed Market

24.65

-2.30 (8.52%)

Volume: 1.57M

Last Updated:

Jan 13, 2026, 3:59 PM EDT

Trade Now

Company Overview: enovis - ENOV

ENOV Key Data

Open

$27.04

 Day Range

24.56 - 27.04

52 Week Range

24.56 - 49.38

 Market Cap

$1.54B

Shares Outstanding

57.19M

 Public Float

56.05M

Beta

1.29

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$24.21

Yield

0.00%

 Dividend

$16.67

EX-DIVIDEND DATE

Apr 5, 2022

 SHORT INTEREST

N/A

AVERAGE VOLUME

897.79K

  

ENOV Performance

1 Week
 
 -16.91%
 
1 Month
 
 -6.84%
 
3 Months
 
 -21.51%
 
1 Year
 
 -47.12%
 
5 Years
 
 -62.98%
 

ENOV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About enovis - ENOV

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

ENOV At a Glance

Enovis Corp.
2711 Centerville Road
Wilmington, Delaware 19808
Phone 1-302-252-9160 Revenue 2.11B
Industry Medical Specialties Net Income -825,494,000.00
Sector Health Technology 2024 Sales Growth 23.455%
Fiscal Year-end 12 / 2025 Employees 7,367
View SEC Filings

ENOV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.151
Price to Book Ratio 0.957
Price to Cash Flow Ratio 21.37
Enterprise Value to EBITDA 13.458
Enterprise Value to Sales 1.795
Total Debt to Enterprise Value 0.371

ENOV Efficiency

Revenue/Employee 286,089.724
Income Per Employee -112,052.939
Receivables Turnover 5.178
Total Asset Turnover 0.457

ENOV Liquidity

Current Ratio 2.167
Quick Ratio 1.133
Cash Ratio 0.091

ENOV Profitability

Gross Margin 48.702
Operating Margin -0.177
Pretax Margin -39.045
Net Margin -39.167
Return on Assets -17.947
Return on Equity -27.692
Return on Total Capital -20.877
Return on Invested Capital -21.078

ENOV Capital Structure

Total Debt to Total Equity 54.807
Total Debt to Total Capital 35.403
Total Debt to Total Assets 29.76
Long-Term Debt to Equity 53.154
Long-Term Debt to Total Capital 34.335
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Enovis - ENOV

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.85B 1.56B 1.71B 2.11B
Sales Growth
+25.52% -59.45% +9.22% +23.46%
Cost of Goods Sold (COGS) incl D&A
2.40B 825.72M 854.02M 1.08B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
262.92M 202.90M 217.10M 284.90M
Depreciation
95.22M 69.20M 76.90M 112.70M
Amortization of Intangibles
167.70M 133.70M 140.20M 172.20M
COGS Growth
+24.23% -65.64% +3.43% +26.60%
Gross Income
1.45B 737.38M 853.18M 1.03B
Gross Income Growth
+27.71% -49.19% +15.70% +20.31%
Gross Profit Margin
+37.65% +47.17% +49.98% +48.70%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.11B 764.13M 857.95M 1.03B
Research & Development
88.80M 60.83M 75.33M 91.30M
Other SG&A
1.03B 703.30M 782.62M 938.89M
SGA Growth
+23.68% -31.45% +12.28% +20.07%
Other Operating Expense
- - - -
-
Unusual Expense
106.71M (39.02M) 65.57M 768.49M
EBIT after Unusual Expense
229.69M 12.27M (70.34M) (772.22M)
Non Operating Income/Expense
9.29M 10.61M 23.16M 7.00M
Non-Operating Interest Income
1.00M 200.00K 200.00K 600.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
73.59M 24.95M 19.95M 57.70M
Interest Expense Growth
-31.52% -66.09% -20.05% +189.24%
Gross Interest Expense
73.59M 24.95M 19.95M 57.70M
Interest Capitalized
- - - -
-
Pretax Income
165.39M (2.07M) (67.13M) (822.92M)
Pretax Income Growth
+185.01% -101.25% -3,144.47% -1,125.90%
Pretax Margin
+4.29% -0.13% -3.93% -39.05%
Income Tax
66.69M 36.12M (13.29M) 4.49M
Income Tax - Current - Domestic
10.04M 8.74M 5.13M 5.34M
Income Tax - Current - Foreign
81.51M 3.40M 9.00M 9.17M
Income Tax - Deferred - Domestic
(13.89M) 73.37M (22.87M) 1.79M
Income Tax - Deferred - Foreign
(10.96M) (49.39M) (4.55M) (11.80M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
98.69M (38.19M) (53.84M) (827.42M)
Minority Interest Expense
4.62M 1.53M 530.00K 679.00K
Net Income
94.07M (39.72M) (54.37M) (828.10M)
Net Income Growth
+54.38% -142.23% -36.87% -1,423.10%
Net Margin Growth
+2.44% -2.54% -3.18% -39.29%
Extraordinaries & Discontinued Operations
(16.21M) 24.73M 5.59M 2.60M
Discontinued Operations
(16.21M) 24.73M 5.59M 2.60M
Net Income After Extraordinaries
77.86M (14.99M) (48.78M) (825.49M)
Preferred Dividends
- - - -
-
Net Income Available to Common
77.86M (14.99M) (48.78M) (825.49M)
EPS (Basic)
1.5224 -0.2773 -0.8951 -14.9328
EPS (Basic) Growth
+34.95% -118.21% -222.79% -1,568.28%
Basic Shares Outstanding
51.14M 54.07M 54.49M 55.28M
EPS (Diluted)
1.5017 -0.2773 -0.8951 -14.9328
EPS (Diluted) Growth
+35.20% -118.47% -222.79% -1,568.28%
Diluted Shares Outstanding
51.85M 54.07M 54.49M 55.28M
EBITDA
599.32M 176.15M 212.33M 281.17M
EBITDA Growth
+24.55% -70.61% +20.53% +32.42%
EBITDA Margin
+15.55% +11.27% +12.44% +13.34%

Snapshot

Average Recommendation BUY Average Target Price 45.90
Number of Ratings 12 Current Quarters Estimate 0.766
FY Report Date 03 / 2026 Current Year's Estimate 3.429
Last Quarter’s Earnings 0.82 Median PE on CY Estimate N/A
Year Ago Earnings 3.181 Next Fiscal Year Estimate 3.868
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 12 11
Mean Estimate 0.77 0.85 3.43 3.87
High Estimates 0.85 0.96 3.58 4.09
Low Estimate 0.67 0.77 3.25 3.58
Coefficient of Variance 7.93 6.55 3.39 5.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 10 9 8
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Enovis - ENOV

Date Name Shares Transaction Value
Apr 2, 2025 Angela S. Lalor Director 13,237 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Daniel Alexis Pryor EVP, Strategy & Business Dev. 151,115 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Patricia A. Lang SVP, Chief HR Officer 54,756 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Bradley J. Tandy SVP and Chief Legal Officer 40,315 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Matthew L. Trerotola CEO; Director 373,514 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Terry Ross GROUP PRESIDENT, P&R 36,114 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 John Kleckner Principal Accounting Officer 10,007 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Phillip Benjamin Berry SVP, Chief Financial Officer 55,983 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Louis Vogt GROUP PRESIDENT, RECON 36,845 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 7, 2025 Brady R. Shirley Director 98,367 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $36.62 per share 3,602,199.54
Feb 20, 2025 Daniel Alexis Pryor EVP, Strategy & Business Dev. 134,307 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.89 per share 5,894,734.23
Feb 20, 2025 Patricia A. Lang SVP, Chief HR Officer 33,979 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.89 per share 1,491,338.31
Feb 20, 2025 Bradley J. Tandy SVP and Chief Legal Officer 28,803 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.89 per share 1,264,163.67
Feb 20, 2025 Brady R. Shirley Director 103,243 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.89 per share 4,531,335.27
Feb 20, 2025 Matthew L. Trerotola CEO; Director 293,360 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $43.89 per share 12,875,570.40

Enovis in the News